These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 30628727)

  • 1. Chronic exercise mitigates disease mechanisms and improves muscle function in myotonic dystrophy type 1 mice.
    Manta A; Stouth DW; Xhuti D; Chi L; Rebalka IA; Kalmar JM; Hawke TJ; Ljubicic V
    J Physiol; 2019 Mar; 597(5):1361-1381. PubMed ID: 30628727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy.
    Lueck JD; Mankodi A; Swanson MS; Thornton CA; Dirksen RT
    J Gen Physiol; 2007 Jan; 129(1):79-94. PubMed ID: 17158949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscleblind-Like 1 and Muscleblind-Like 3 Depletion Synergistically Enhances Myotonia by Altering Clc-1 RNA Translation.
    Choi J; Personius KE; DiFranco M; Dansithong W; Yu C; Srivastava S; Dixon DM; Bhatt DB; Comai L; Vergara JL; Reddy S
    EBioMedicine; 2015 Sep; 2(9):1034-47. PubMed ID: 26501102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vorinostat Improves Myotonic Dystrophy Type 1 Splicing Abnormalities in DM1 Muscle Cell Lines and Skeletal Muscle from a DM1 Mouse Model.
    Neault N; Ravel-Chapuis A; Baird SD; Lunde JA; Poirier M; Staykov E; Plaza-Diaz J; Medina G; Abadía-Molina F; Jasmin BJ; MacKenzie AE
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hallmarks of myotonic dystrophy type 1 muscle dysfunction.
    Ozimski LL; Sabater-Arcis M; Bargiela A; Artero R
    Biol Rev Camb Philos Soc; 2021 Apr; 96(2):716-730. PubMed ID: 33269537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of MTMR1 expression and correlation with muscle pathological features in juvenile/adult onset myotonic dystrophy type 1 (DM1) and in myotonic dystrophy type 2 (DM2).
    Santoro M; Modoni A; Masciullo M; Gidaro T; Broccolini A; Ricci E; Tonali PA; Silvestri G
    Exp Mol Pathol; 2010 Oct; 89(2):158-68. PubMed ID: 20685272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age of onset of RNA toxicity influences phenotypic severity: evidence from an inducible mouse model of myotonic dystrophy (DM1).
    Gladman JT; Mandal M; Srinivasan V; Mahadevan MS
    PLoS One; 2013; 8(9):e72907. PubMed ID: 24039817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1.
    de Haro M; Al-Ramahi I; De Gouyon B; Ukani L; Rosa A; Faustino NA; Ashizawa T; Cooper TA; Botas J
    Hum Mol Genet; 2006 Jul; 15(13):2138-45. PubMed ID: 16723374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aerobic exercise elicits clinical adaptations in myotonic dystrophy type 1 patients independently of pathophysiological changes.
    Mikhail AI; Nagy PL; Manta K; Rouse N; Manta A; Ng SY; Nagy MF; Smith P; Lu JQ; Nederveen JP; Ljubicic V; Tarnopolsky MA
    J Clin Invest; 2022 May; 132(10):. PubMed ID: 35316212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.
    Christou M; Wengel J; Sokratous K; Kyriacou K; Nikolaou G; Phylactou LA; Mastroyiannopoulos NP
    Nucleic Acid Ther; 2020 Apr; 30(2):80-93. PubMed ID: 31873063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy.
    Fugier C; Klein AF; Hammer C; Vassilopoulos S; Ivarsson Y; Toussaint A; Tosch V; Vignaud A; Ferry A; Messaddeq N; Kokunai Y; Tsuburaya R; de la Grange P; Dembele D; Francois V; Precigout G; Boulade-Ladame C; Hummel MC; Lopez de Munain A; Sergeant N; Laquerrière A; Thibault C; Deryckere F; Auboeuf D; Garcia L; Zimmermann P; Udd B; Schoser B; Takahashi MP; Nishino I; Bassez G; Laporte J; Furling D; Charlet-Berguerand N
    Nat Med; 2011 Jun; 17(6):720-5. PubMed ID: 21623381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HNRNPA1-induced spliceopathy in a transgenic mouse model of myotonic dystrophy.
    Li M; Zhuang Y; Batra R; Thomas JD; Li M; Nutter CA; Scotti MM; Carter HA; Wang ZJ; Huang XS; Pu CQ; Swanson MS; Xie W
    Proc Natl Acad Sci U S A; 2020 Mar; 117(10):5472-5477. PubMed ID: 32086392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Furamidine Rescues Myotonic Dystrophy Type I Associated Mis-Splicing through Multiple Mechanisms.
    Jenquin JR; Coonrod LA; Silverglate QA; Pellitier NA; Hale MA; Xia G; Nakamori M; Berglund JA
    ACS Chem Biol; 2018 Sep; 13(9):2708-2718. PubMed ID: 30118588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing.
    Charlet-B N; Savkur RS; Singh G; Philips AV; Grice EA; Cooper TA
    Mol Cell; 2002 Jul; 10(1):45-53. PubMed ID: 12150906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Overview of Alternative Splicing Defects Implicated in Myotonic Dystrophy Type I.
    López-Martínez A; Soblechero-Martín P; de-la-Puente-Ovejero L; Nogales-Gadea G; Arechavala-Gomeza V
    Genes (Basel); 2020 Sep; 11(9):. PubMed ID: 32971903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy.
    Mahadevan MS; Yadava RS; Yu Q; Balijepalli S; Frenzel-McCardell CD; Bourne TD; Phillips LH
    Nat Genet; 2006 Sep; 38(9):1066-70. PubMed ID: 16878132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy.
    Bisset DR; Stepniak-Konieczna EA; Zavaljevski M; Wei J; Carter GT; Weiss MD; Chamberlain JR
    Hum Mol Genet; 2015 Sep; 24(17):4971-83. PubMed ID: 26082468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy.
    Osborne RJ; Lin X; Welle S; Sobczak K; O'Rourke JR; Swanson MS; Thornton CA
    Hum Mol Genet; 2009 Apr; 18(8):1471-81. PubMed ID: 19223393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models.
    Cerro-Herreros E; Sabater-Arcis M; Fernandez-Costa JM; Moreno N; Perez-Alonso M; Llamusi B; Artero R
    Nat Commun; 2018 Jun; 9(1):2482. PubMed ID: 29946070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1.
    Ward AJ; Rimer M; Killian JM; Dowling JJ; Cooper TA
    Hum Mol Genet; 2010 Sep; 19(18):3614-22. PubMed ID: 20603324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.